EPO and anemia (phenotype): Suppressing the release of erythropoietin from kidney interstitial cells might benefit patients during erythrocyte transfusion at higher hemoglobin thresholds (e.g., 9–10 g/dL), even in the absence of clinical signs of anemia [120,121].